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ABSTRACT
Introduction: We compared in vitro drug
delivery characteristics of two
budesonide/formoterol dry powder inhalers,
the Bufomix Easyhaler and the
budesonide/formoterol Turbuhaler, at
different patient air flow rates, and to test dose
delivery from the Easyhaler in stressed
conditions exposed to moisture, dropping,
vibration and freezing/thawing.
Methods: A total of 36 inhalers from two
batches of both products (160/4.5 lg strength)
were used when comparing the effect of flow
rate; six inhalers for each of the three flow rates
for uniformity of delivered dose (DD), fine
particle dose (FPD), mass median aerodynamic
diameter (MMAD) and geometric standard
deviation (GSD). Consistency of DD, FPD,
MMAD and GSD were determined for each
inhaler at three different flow rates: 10th, 50th
and 90th percentile air flows. Dosing properties
as a function of inhaler life were tested. The
effects of moisture, dropping, vibration and
freezing/thawing on DD and FPD were tested
with two to four inhalers per test using all three
strengths of Easyhaler: 80/4.5, 160/4.5 and
320/9 lg.
Results: The Easyhaler, 160/4.5 lg, showed
statistically significantly better dose
consistency (expressed as percentage of
labelled dose) at all three inhalation flows
compared with the Turbuhaler, 160/4.5 lg,
(p\0.001 for three flow rates). Exposure to
moisture, dropping, vibration and freezing/
thawing did not affect DD or FDP. These
results were similar to all three tested
Easyhaler strengths.
Conclusion: In vitro performance of the
Easyhaler indicates reliable dosing. Dose
consistency was superior compared with the
Turbuhaler at all tested flow rates.
Environmental moisture, dropping, vibration
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and freezing/thawing did not affect the
performance.
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INTRODUCTION
Inhaler devices containing an inhaled
corticosteroid (ICS) and a long-acting
b2-agonist (LABA) are widely used for the
treatment of specified patient groups with
asthma and chronic obstructive pulmonary
disease (COPD) [1]. The first combination
inhaler on the market containing the ICS
budesonide and the LABA formoterol fumarate
dihydrate (hereafter formoterol) was the
Symbicort Turbuhaler (AstraZeneca, UK).
Recently, secondary entry products containing
the same active substances have been
developed, among them the
budesonide/formoterol Easyhaler (Bufomix
Easyhaler, Orion Corporation Orion Pharma,
Finland). Regulatory approval of the
budesonide/formoterol Easyhaler was based on
the demonstration of therapeutic equivalence
(lung dose and systemic exposure) with the
budesonide/formoterol Turbuhaler [2–4].
A prerequisite for any inhaler device used for
the treatment of airway diseases is that it should
perform consistently, delivering a
predictable and reproducible drug dose during
repeated use, i.e. from the first to the last
labelled dose. The inhaled particles should also
have a size making them respirable, i.e. particles
of aerodynamic size B5 lm [5]. Depending on
the particle size distribution, the lung
deposition may be central or more peripheral.
Particles smaller than 1 lm are exhaled to a
large degree [5]. Due to differences in
construction and powder formulation, great
variations in aerodynamic particle sizes have
been reported for dry powder inhalers (DPI) [6].
Criteria for the predictability of inhaler
performance are required for successful
management of asthma and COPD.
The Easyhaler is a multi-dose reservoir-type
DPI used to deliver a wide range of various
medications, the latest addition being the
budesonide/formoterol combination product.
The budesonide/formoterol Easyhaler is
available in three strengths: 80/4.5, 160/4.5
and 320/9 lg/inhalation.
The Easyhaler is inspiratory flow-driven and,
therefore, its performance is dependent on the
inspiratory effort produced by the patient, the
built-in resistance of the inhaler, as well as the
aerosolization geometry of the device [7]. It has
been previously shown that with clinically
relevant flow rates, delivered doses (DD) and
fine particle doses (FPD) are rather independent
of flow rates with the budesonide/formoterol
Easyhaler and budesonide/formoterol
Turbuhaler [3], although in vitro
flow-dependent properties of, e.g., the
Turbuhaler have been reported [8]. However,
the inspiratory effort may vary considerably
from one patient to another and, thereby,
potentially affecting the clinical efficacy of the
product.
A previous study determined the mean
inspiratory flow rates through the
budesonide/formoterol Easyhaler and
Turbuhaler in patients with COPD and in
children and adults with asthma [3]. For the
Easyhaler, the flow rates were 55.8 (13.0) L/min
[standard deviations (SD)] in patients with
COPD, 61.0 (11.1) L/min (SD) in asthmatic
children, and 63.7 (11.5) L/min (SD) in adults
with asthma. For the Turbuhaler, the
corresponding mean values (SD) were 72.1
(15.1), 76.5 (14.1), and 79.4 (14.4) L/min [3].
An air flow resistance of 0.032 kPa0.5 min/L was
documented for the budesonide/formoterol
Turbuhaler while the resistance for the
budesonide/formoterol Easyhaler was
0.036 kPa0.5 min/L [3]. Thus, both the
budesonide/formoterol Easyhaler and
budesonide/formoterol Turbuhaler could be
described as medium-resistance devices [5]. For
comparison, a study by Delvadia et al. showed a
resistance of the budesonide Turbuhaler of
0.035 kPa0.5 min/L and for the salbutamol
Easyhaler of 0.0435 kPa0.5 min/L [9]. Thus, the
difference between flow rates through inhalers
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depends on the difference in their intrinsic
resistance [9].
In this study, we wanted to compare the
uniformity of the in vitro DD of the
budesonide/formoterol Easyhaler and
Turbuhaler and to analyze some key in vitro
characteristics of the products such as FPD,
mass median aerodynamic diameter (MMAD)
and geometric standard deviation (GSD).
Additionally, the dosing properties (DD and
FPD) through the inhaler life were tested. We
also exposed the Easyhaler to various stress tests
such as moisture, dropping, vibration and
freezing/thawing in order to assess the




Orion Corporation Orion Pharma provided the
budesonide/formoterol Easyhaler inhalers. The
Easyhaler is a multi-dose, breath-actuated DPI
containing budesonide and formoterol
fumarate with lactose as carrier.
For the comparative dose uniformity studies
versus the Turbuhaler, the commercially
available reference products, the
budesonide/formoterol Turbuhaler inhalers
containing 160/4.5 lg per dose of budesonide
and formoterol (Symbicort), were used. A total
of 54 inhalers from two batches of each product
were used when comparing the effect of flow
rate.
For the test of dose uniformity over the
lifetime of the Easyhaler inhaler, two batches
and three inhalers per batch from all strengths,
80/4.5, 160/4.5 and 320/9 lg/inhalation, were
used; i.e. 3 9 18 = 54 inhalers.
For the environmental exposure and
robustness tests, three inhalers were used for
determination of DD and three for FPD.
Methods
The Orally Inhaled Product (OIP) guideline [10]
and Pharmaceutical Quality on the Inhalation
and Nasal Products guideline [11] address the
need to perform a product comparison using air
flows that are characteristic for the targeted
patient population. Flow rate dependency of
The Easyhaler and Turbuhaler inhalers was
assessed with flow rate ranges achieved by the
study patient population of an earlier study [3].
The minimum (10th percentile), median (50th
percentile) and maximum (90th percentile)
flow rates were used for DD and FPD
measurements and are shown for both
products in Table 1. The figures represent the
patient sub-group proportions within the whole
indicated patient population, and then
balancing of the achievable sub-group flow
rates accordingly [3].
Delivered Dose
DD was determined by using the sampling
apparatus and procedure described in the
European Pharmacopoeia [12]. Four liters of air
were drawn through the inhaler at a flow rate
corresponding to a 4-kPa pressure drop across
the device. The number of doses collected is
specified in tests characterized below.
Budesonide and formoterol fumarate collected
in the sampling apparatus were dissolved with
50:50 (v/v) water:methanol and samples were
analyzed by high-performance liquid
chromatography (HPLC).
Fine Particle Dose
FPD (\5 lm) was determined using a
next-generation impactor (NGI) equipped with
a pre-separator according to the procedure
described in the European Pharmacopoeia. For
each FPD analysis, ten doses were discharged
into the NGI at a flow rate corresponding a
4-kPa pressure drop across the inhaler. NGI
stages were coated with DS-515 Dekati
collection substrate spray in order to eliminate
particle bounce and re-entrainment, which may
distort impactor measurements. Then, the doses
were collected in the NGI, and the powder
deposited on the surfaces was quantitatively
recovered with 50:50 (v/v) water:methanol and
the samples were analyzed by HPLC. In every
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FPD analysis conducted, it was verified that the
mass balance was within ±15% of the delivered
dose result of the batch.
MMAD and GSD values were determined from
the measurements at the flow rates shown in
Table 1 and were calculated from the number of
particles deposited at different stages of the NGI.
Delivered Dose and Fine Particle Dose
Through the Easyhaler Lifetime
The aim was to determine DD and FPD as a
function of dosing interval. DD analyses were
done at the beginning, middle and end of the
labelled number of doses. FPD analyses were
done at the beginning and end of the labelled
number of doses. The number of doses analyzed
through container life is presented in Table 2.
Effect of Moisture
Delivered dose was analyzed from the first five
doses. After the fifth dose, the inhalers without
an aluminum laminate pouch were placed in a
30 C/75% relative humidity (RH) storage
condition for 48 h. After storage, the next five
doses were analyzed. The FPD was analyzed
from the first ten doses. After the tenth dose,
the inhalers without an aluminum laminate
pouch were placed in a 30 C/RH75% storage
condition for 48 h. After storage, the next ten
doses were analyzed.
Effect of Dropping
The dropping test was carried out according to
the principles described in the ISO/FDIS
20072:2009 standard by dropping inhalers on a
wooden surface from one meter height [13]. For
this test, two Easyhaler inhalers from one batch
were used and the DD and FPD were analyzed.
Measurements were done both in the beginning
and at the end of the labelled number of doses.
DD was determined from three doses before the
inhaler was dropped. After dropping, the DD
from three doses were analyzed again. In the
beginning of the labelled number doses, FPD was
analyzed before and after the drop from the same
inhaler, while toward the end of doses, FPD was
analyzed from a dropped inhaler and an inhaler
which had not been dropped. For the inhalers
80/4.5 and 160/4.5 lg, the inhaler doses 111–120
were analyzed after dropping and without
dropping. For the 320/9 lg inhaler, the doses
51–60 were analyzed in a similar way.
Effect of Vibration
The aim of the vibration test was to simulate
inhaler transportation and especially the
Table 1 Flow rate values (L/min) of different ﬂow rate percentiles for the budesonide/formoterol Easyhaler and
Turbuhaler
Inhaler 10th percentile Median (50th
percentile)
90th percentile




Table 2 Delivered doses (DD) and ﬁne particle doses (FPD) analyzed through inhaler lifetime




DD 1–3, 59–62, and 118–120 1–3, 29–32, and 58–60
FPD 1–10 and 111–120 1–10 and 51–60
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vibration caused by the transportation. The DD
and FPD were determined after the products
were exposed to vibration stress. The vibration
test was carried out in the vertical axis
according to the publication IEC 60068-2-64,
test Fh (2008-04) [14]. The test duration was
60 min and the test level conditions were as
follows: frequency range 5–500 Hz, acceleration
spectral density (ASD) level 1 m2/s3 5–20 Hz,
ASD level 3 decibels/octave 20–500 Hz, total
spectral acceleration 0.9 g, and uncertainty of
measurements 5%. The DD and FPD results after
vibration were compared to DD and FPD results
of inhalers from the same batch that had not
been vibrated. Two batches and two inhalers per
batch were studied.
Effect of Freezing/Thawing
For the freeze/thaw study, the
budesonide/formoterol Easyhaler inhaler was
subject to three freeze/thaw cycles over
2 weeks. The Easyhaler inhaler 160/4.5 lg/
inhalation, 120 doses, was selected as it covers
the product containing 60 doses. The product
was kept in a freezer (temperature target:
-20 C; ± 5 C) for 2 days (or 3 days on
weekends) as such without the laminate
package or in the laminate package. After the
inhalers were removed, they were transferred
into elevated temperature (25 ± 2 C; 60% ± 5%
RH) for 2 days (or 3 days on weekends). The
samples were then removed and transferred
into the freezer for 2 days and so on for a total
of three freezing/thawing cycles. After the third
freeze/thaw cycle, the FPD and DD were
analyzed.
Reference samples inside a laminate pouch
were kept in a 25 C/60% RH condition for the
same time as three freeze/thaw cycles (2 weeks).
They were not subjected to freezing. After
2 weeks, FPD and DD were analyzed.
HPLC Quantitation of Budesonide
and Formoterol Fumarate
Budesonide and formoterol fumarate was
determined from all samples by using validated
HPLC. The method used a Spherisorb ODS-1
column (5 lm, 4.0 9 250 mm) with a mobile
phase consisting 0.015 M sodium dihydrogen
phosphate monohydrate buffer (pH 2.1) and
acetonitrile (50:50, v/v). Mobile phase was
delivered at a flow rate of 1.5 mL/min and
injection volume was 30 lL. UV detection at
214 nm and a run time of 10 min was used.
Samples were dissolved in H2O:methanol (50:50,
v/v). The quantitation limits of budesonide and
formoterol fumarate were 0.5 and 0.02 lg/mL,
respectively. The linearity of response of
budesonide and formoterol fumarate was
0.5–100 and 0.02–2.5 lg/mL, respectively.
Statistical Analyses
Mean values and SD were calculated for the
delivered doses from the budesonide/formoterol
Easyhaler and Turbuhaler at the three different
flow rates. The equality of variance was assessed
for all different flow rates using Levene’s test
because of the non-normality of the data with a
significance level of 0.05. The null hypothesis of
equal variances is rejected with p values less than
the significance level and it is concluded that
there is a statistically significant difference
between the variances. All statistical analyses
were performed with Minitab version 17
(Minitab Inc., State College, PA, USA).
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent was not applicable as
there is no clinical data.
RESULTS
Delivered Doses and Fine Particle Doses
Over Patient Flow Rate Range
Figure 1 shows the DD of budesonide (Fig. 1a)
and formoterol (Fig. 1b) at the three different
flow rates expressed as a percent of the labelled
doses delivered from the budesonide/formoterol
Easyhaler and Turbuhaler. The variability in dose
delivery from the Easyhaler was statistically
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significantly smaller than from the Turbuhaler
for both budesonide and formoterol and this was
true at all three flow rates.
For budesonide at a 10th percentile air flow,
the mean delivered dose (SD) was 159 (14) lg/
inhalation for the Easyhaler and 148 (24) lg/
inhalation for the Turbuhaler. The p value for
the difference was p = 0.004. For the median
percentile air flow, the corresponding
figures were 169 (14) lg/inhalation for the
Easyhaler and 155 (39) for the Turbuhaler
(p\0.001). For the 90th percentile air flow,
the figures were 175 (13) lg/inhalation for the
Easyhaler and 153 (35) lg/inhalation for the
Turbuhaler (p\0.001).
For formoterol at a 10th percentile air flow,
the mean delivered dose (SD) was 4.1 (0.4) lg/
inhalation for the Easyhaler and 4.1 (0.7) lg/
inhalation for the Turbuhaler. The p value for
the difference was p = 0.002. For the median
percentile air flow, the corresponding
figures were 4.6 (0.4) lg/inhalation for the
Easyhaler and 4.3 (1.0) for the Turbuhaler
(p\0.001). For the 90th percentile air flow,
the figures were 4.7 (0.4) lg/inhalation for the
Easyhaler and 4.2 (1.0) lg/inhalation for the
Turbuhaler (p = 0.001).
Figure 2 shows the DD (Fig. 2a) and the FPD
(Fig. 2b) of the three strengths of the
budesonide/formoterol Easyhaler at the three
Fig. 1 a, b Dose
delivery of budesonide








4.5 lg) at three differ-
ent ﬂow rates. The
delivered dose is




a single dose actuation
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different flow rates [the minimum (10th
percentile), median (50th percentile) and
maximum (90th percentile) flow].
Delivered Doses and Fine Particle Doses
Throughout the Budesonide/Formoterol
Easyhaler Inhaler Lifetime
Figure 3a shows the DD of the three
budesonide/formoterol Easyhalers taken in the
beginning (doses 1–3), at the middle and at the
end of the Easyhaler lifespan when the first
doses are set to 100%. Overall, DD varied from
94% to 103% for the three presentations at the
middle and at the end of the Easyhaler content.
Fig. 3b shows FPD of doses at the beginning and
at the end of the Easyhaler.
It is concluded that the influence of the
number of actuations had only a slight effect on
product properties. Additionally, DD and FPD
show that patients can inhale the correct dose
throughout the inhaler life.
Mass Median Aerodynamic Diameter
and Geometric Standard Deviation
MMAD values (lm) and GSD for the
budesonide/formoterol Easyhaler and
budesonide/formoterol Turbuhaler at the
different flow rates are presented in Table 3.
Higher flows resulted in lower MMADs for
both inhalers when going from the 10th
percentile of flow rates to the 90th
percentile. For budesonide, MMAD decreased
for the Easyhaler from 2.5 to 2.2 lm and for
the Turbuhaler, from 2.3 to 2.0 lm. The
corresponding values for formoterol were
from 3.0 to 2.7 lm for the Easyhaler, and
from 2.7 to 2.5 lm for the Turbuhaler. GSDs
of the particle size distributions were the same
Fig. 3 a Delivered doses of 80/4.5, 160/4.5 and 320/9 lg
in the budesonide/formoterol Easyhaler from the begin-
ning (100%), the middle, and the end of inhaler lifespan
expressed as deviations ± SD (n = 6); b corresponding
values for ﬁne particle dose (n = 6)
Fig. 2 a Delivered doses of 80/4.5, 160/4.5 and 320/9 lg
in the budesonide/formoterol Easyhaler at three different
ﬂow rates (10th, 50th and 90th percentiles ﬂow) expressed
as deviations (±SD) from the 50th percentile ﬂow rate
which is marked as 100%; b corresponding values for ﬁne
particle dose
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between the products through the different
flow rates.
Delivered Doses and Fine Particle Doses
after Dropping, Vibration or Freezing/
Thawing
The effect of environmental moisture (30 C/
75% RH) on DD of the three strengths of the
budesonide/formoterol in Easyhaler is shown in
Fig. 4a. With the initial value set to 100%, the
deviations from 100% after exposure were
minor. The effect on FPD is shown in Fig. 4b.
Dropping the Easyhaler from one meter
height did not result in changes in DD of
budesonide or formoterol (Fig. 5). The DD of
three doses in the beginning of the inhaler life
before and after dropping is shown in Fig. 5a
and at the end of the inhaler life, in Fig. 5b.
Dropping did not influence DD of either
budesonide or formoterol.
The results of the vibration tests are shown
in Fig. 6a (DD) and Fig. 6b (FPD). When the DD
without vibration was set to 100%, the
deviations for the three doses of the
budesonide/formoterol Easyhaler varied from
99% to 103% for budesonide and from 100% to
104% for formoterol. The corresponding values
for FPD were 97–104% for budesonide and from
100% to 107% for formoterol. Thus, vibration
did not affect DD or FDP of the
budesonide/formoterol Easyhaler.
The results of the freezing/thawing tests are
shown in Fig. 6c (DD) and Fig. 6d (FPD). When
the reference values are set to 100% (the
160/4.5 lg Easyhaler product), the DD values
for budesonide after the freezing/thawing
procedure were 98% for the inhaler as such
and 99% for the laminated package, and 100%
and 104% for formoterol. The FPD values were
95% and 96% for budesonide and 97% for
formoterol (both presentations). Thus, freezing
and thawing did not affect the DD and FPD of
the budesonide/formoterol Easyhaler.
DISCUSSION
Since the early introduction of multi-dose DPIs,
investigators and reviewers have discussed the
function of the devices, i.e. the built-in
Table 3 Mass median aerodynamic diameter at different ﬂow rate percentiles for the budesonide/formoterol Easyhaler and
budesonide/formoterol Turbuhaler







Easyhaler 2.5/3.0 2.3/2.8 2.2/2.7
Turbuhaler 2.3/2.7 2.1/2.5 2.0/2.5
Fig. 4 a, b Effect of moisture on delivered dose of 80/4.5, 160/4.5 and 320/9 lg in the budesonide/formoterol Easyhaler
(n = 2); b corresponding values for ﬁne particle dose
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resistance, the required inspiratory flow/effort,
and the consistency of dose delivery. Most
recently, these questions were discussed in a
review by Dal Negro [15]. According to him, a
DPI should (1) be effective, i.e. able to consent
the inhalation of a sufficient fraction of drug
with a particle size B6 l, independently of the
patient’s inspiratory flow; (2) reproducible, i.e.
able to always consent to the inhalation of the
same drug amount, also in terms of its
respirable fraction; (3) precise, i.e. able to
consent to know at any moment (or the
number of doses) of the drug remaining in the
device, and whether or not the inhalation was
correctly performed: thus, the need for
providing DPIs of a ‘‘dose counter’’ and of a
‘‘double-dosing protection counter’’, in order to
avoid a further inhalation if the patient is
unaware or not sure of having taken the
previous one; (4) stable. i.e. able to protect the
drug(s) contained from the effects of
temperature and/or humidity changes; (5)
Fig. 5 a, b Effect of dropping (n = 2) on the delivered dose of the inhaler in the beginning of the inhaler life (Fig. 5a) and
at the end (Fig. 5b)
Fig. 6 a–d Effect of vibration on delivered dose (Fig. 6a)
and ﬁne particle dose (Fig. 6b) of 80/4.5, 160/4.5 and
320/9 lg in the budesonide/formoterol Easyhaler. Effect
of freezing/thawing on delivered dose (Fig. 6c) and ﬁne
particle dose (Fig. 6d) of 80/4.5, 160/4.5 and 320/9 lg in
the budesonide/formoterol Easyhaler
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comfortable, i.e., easy to use in different
circumstances (particularly in clinical
conditions) and possibly containing several
doses of the drug(s) for a long-term use; (6)
versatile, i.e. it should consent to the use of
other drugs by inhalation; and (7)
environmentally compatible, i.e. not
containing chemical contaminants.
Commercially available DPIs do not fulfill all
the above-mentioned criteria perfectly. All
requirements may be achievable but at a
complicated design and high cost. Therefore,
for practical reasons, compromises have to be
made, especially from a cost-effectiveness point
of view. We can hope for the ‘‘ideal inhaler’’ but
have to live with the ‘‘real-life inhaler’’ [16].
Previous reviews of in vitro performances of
the Easyhaler inhaler concluded that the device,
compared with other DPIs on the market, came
closer to the ‘‘ideal inhaler’’ than many other
inhalers [17, 18]. The comparison was mainly
made versus the Turbuhaler inhaler—the first
multi-dose reservoir DPI on the market.
The second entry of a budesonide/formoterol
DPI, the Easyhaler, has been granted marketing
authorization based on established therapeutic
equivalence in comparison with the original
product, the budesonide/formoterol
Turbuhaler, according to the current European
guidelines [2–4].
For comparison of orally inhaled products, it
is essential to understand the performance of
the products in the hands of different patient
groups, i.e. asthmatic children and adults, and
patients with COPD. The recent European
Guideline on the requirements for clinical
documentation for orally inhaled products,
including the requirements for demonstration
of therapeutic equivalence between two inhaled
products for use in the treatment of asthma and
COPD in adults and for use in the treatment of
asthma in children and adolescents, requires
in vitro flow dependency studies applying, e.g.
10th percentile, 50th (median) and 90th
percentile, achievable air flow rates by the
targeted patient population [10]. For the
Easyhaler and Turbuhaler, the achievable air
flow rates have been previously described [3]. In
the current study, the final version of the
budesonide/formoterol Easyhaler inhaler was
compared with the commercially available
budesonide/formoterol Turbuhaler inhaler.
The achievable air flow is determined by the
air flow resistance of the device. The higher the
resistance, the lower the achievable air flow.
According to pharmacopoeias, in vitro studies
should be carried out using a 4-kPa pressure
drop through the inhaler [12]. Recently, a lot of
progress has been made concerning more
realistic in vitro measurements applying
anatomical throats instead of pharmacopeia
USP throat, e.g. Alberta idealised throat (AIT)
[19], other more realistic physical airway
models [20] as well as anatomically correct
inlet throats [21]. In addition, different
authors have published substantial work
related to the use of more realistic patient air
flow profiles, e.g. Koening et al. [22] and
Delvadia et al. [23]. These advanced methods
in combination with pharmacokinetic results
would possibly establish more depth of
understanding in vitro/in vivo (IVIV)
correlation between different products and
provide valuable tools for the development in
the future. That will be the subject of further
work in the future for us. The reported studies
have been carried out based on pharmacopeial
standard methods as that approach is in line
with current regulatory requirements. A
combination of this work in addition to
Malmberg et al. [3] and La¨helma¨ et al. [4, 24]
provides an overview for the performance of the
budesonide/formoterol Easyhaler and
Turbuhaler in vitro and in hands of the
patients.
The air flow dependency of FPD of both
products was demonstrated in the flow
dependency study [3]. Further analysis of
single delivered doses in that study showed
that the Easyhaler dose delivery worked
accurately and repeatedly across different flow
rates. A similar finding was reported in an
earlier study conducted with salbutamol
Easyhaler and Turbuhaler devices [25]. Since
then, the Turbuhaler device has been updated
for some products, including
budesonide/formoterol. The new
budesonide/formoterol Turbuhaler device
incorporates a printed dose counter and has a
slightly reduced air flow resistance compared to
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the earlier Turbuhaler versions marketed with
the single components, e.g. budesonide or
formoterol [26, 27].
In this study, we further evaluated the flow
rate dependency of all three
budesonide/formoterol Easyhaler
presentations, i.e. 80/4.5, 160/4.5 and 320/9 lg
at the three different flow rate ranges achieved
by the study patient population in an earlier
study [3]. The minimum (10th percentile),
median (50th percentile) and maximum (90th
percentile) flow rates were used for DD and FPD
measurements. The same presentations of the
budesonide/formoterol Turbuhaler were used
and consistency of dose delivery was
compared. The study showed a statistically
significantly better dose consistency for the
Easyhaler compared with the Turbuhaler at all
three levels of tested flow rates. Thus, the
excellent dosing accuracy of the Easyhaler
documented with other substances has been
maintained with budesonide/formoterol. It can
be speculated that the detected difference in
dosing accuracy characteristics could
potentially relate to differences in formulation
and device technology between the Easyhaler
and Turbuhaler. The mass and volume of a dose
is fairly small in the Turbuhaler (160/4.5 lg/
inhalations strength approx. 0.94 mg, whereas
in the Easyhaler, it is approximately 4.0 mg)
and, therefore, the Turbuhaler has a higher
concentration of drug substance than the
Easyhaler. The small volume and high
concentration could lead to some lack of
control in dosing volume and drug retention
to the plastic surfaces of the inhalers. If drug
retention occurs in an inhaler, it could
potentially sometimes lead to lower and
higher doses than normally, which could be
an interesting subject of a further study. For
lactose, besides the important formulation
function as a carrier of the drug substance, a
sufficient amount may additionally provide the
patient with the feedback of received dose by
taste.
From previous studies, it is well known that
MMAD of the Turbuhaler is dependent on the
inspiratory flow [28, 29]. In our study, we used
the same 10th, median and 90th percentile
patient flow rates as when studying DD
uniformity. The MMADs and GSDs were very
similar for the Easyhaler and Turbuhaler
throughout the different patient flow rates. In
another in vitro study using clinically relevant
patient air flow rates, a slight flow-dependent
increase in FPD was found for both budesonide
and formoterol for both the devices [3]. In
contrast, the Turbuhaler has earlier been
reported being a highly air flow-dependent
device [8, 30]. That conclusion may have
partially been drawn from performance
characteristics with low air flows, e.g. 30 L/
min, which is far below the applicable 10th
percentile air flow of 54 L/min reported by
Malmberg et al. [3] and also reported by
Brown et al. for the Turbuhaler [31].
Concerning the flow rate resistance, the DPIs
with a high built-in air flow resistance give the
best lung penetration because it reduces the
velocity of the aerosol particles in the respiratory
tract [32]. The preferences of patients and healthy
volunteers for resistance have been studied with
different outcomes. In one study, the highest
preference was found for a low-resistance inhaler
(0.015 kPa0.5 min/L) by asthmatics and COPD
patients [33]. In contrast, in another study, 82%
of the healthy volunteers gave preference for a
moderate- or high-resistance inhaler
(0.021–0.047 kPa0.5 min/L) [34]. The conflicting
aspects of patient preferences (moderate to low
resistance) and lung penetration (high resistance)
may find an optimal solution with inhalers, such
as the Easyhaler and Turbuhaler, having a
medium resistance (e.g. 0.032–0.036 kPa0.5 min/
L) [32]. Clinical experience shows that most
patients can use a medium- to high-resistance
DPI effectively, even during exacerbations
[30, 31].
DPIs may be affected by environmental
factors. A patient-reported survey indicates
that two-thirds of the patients store their
inhaler devices in suboptimal conditions, and
only a minority had received instruction
regarding inhaler handling [35]. These
Easyhaler studies showed that the Easyhaler is
tolerant to real-life environmental stress as DD
and FPD are virtually unaffected by
environmental factors.
Pulm Ther
What are the possible clinical implications of
our findings? In the end, it is the clinical
efficacy and safety that determines the
usefulness of the inhalers. Also, inhaler
handling easiness and patient preferences
should be considered as important elements of
patient adherence to the treatment. As stated in
the recent European consensus statement (5),
patients should be prescribed inhalers that they
can and will use. In addition to
pharmacokinetic studies [4], appropriate
in vitro comparisons between products for
flow rate dependency [3], particle size
distributions and dosing accuracy with a target
population of relevant flows are needed to
support therapeutic equivalence. Based on our
results and the previously published studies
[3, 4, 24], there is no reason to believe that
differences in clinical safety and efficacy would
be demonstrable between the two tested
inhalers.
The MMAD and GSD of the particles in the
budesonide/formoterol Easyhaler are
comparable with particles of the
budesonide/formoterol Turbuhaler over the
different patient flow ranges. The Easyhaler
appears to be robust in dosing accuracy and is
a viable device for treatment of patients with
asthma and COPD.
Limitations of the current study: as discussed
above, our paper reports studies that have been
carried out based on pharmacopeial standard
methods which are in line with current
regulatory requirements. However, progress
has been made in developing more advanced
in vitro methods to mimic the patients’
inspiratory flow profiles to further improve
their applicability to real-world situations
where inhalers are used.
CONCLUSION
The results of studies reported here indicate that
the budesonide/formoterol Easyhaler delivers
consistently accurate doses throughout inhaler
life. Dose consistency was superior compared
with the budesonide/formoterol Turbuhaler at
all tested flow rates. Consistency of overall
dosing was maintained under exposure of the
inhaler to stressed conditions as variations in
temperature and humidity as well as after
dropping, vibration and freeze/thaw tests.
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